Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.40 |
| ▸ | ACHE | P22303 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22326281 | 1.00 | MEN1 (0.45) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL22326294 | 1.00 | MEN1 (0.45) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL21070962 | 0.98 | MEN1 (0.48) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL22326327 | 0.98 | MEN1 (0.48) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL25369822 | 0.98 | MEN1 (0.42) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL21070920 | 0.96 | MEN1 (0.45) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL21069080 | 0.94 | MEN1 (0.46) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL19306452 | 0.92 | TSHR (0.43) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL25385542 | 0.85 | MEN1 (0.50) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL23636435 | 0.85 | MEN1 (0.50) | MEN1KMT2ATHRBHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727355-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | MEN1 474/4885KMT2A 2404/4885THRB 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.